For Partners · By invitation
Where APAC MedTech's next moves get built.
We read every annual filing in the APACMed MedTech membership, plus ten global peers outside it. The fifteen challenges in this programme are not our opinion — they are a count of what these companies wrote down, under legal obligation, in documents lodged with securities regulators.
Amplifai — APACMed's official three-year innovation program (2026–2028).
Top 15 challenges, ranked
Curated from APACMed member research — with the solution angle and evidence trail for each.
Verified solvers
A vetted roster of APAC and non-APAC providers, with warm, double opt-in introductions. Timing is confirmed at intake.
Private by design
No member sees another member's activity. Data stays in Singapore. PDPA-first.
The signature module
What 62 MedTech companies name as a risk — in their own filings
Not a survey. Not an estimate. A count of how many of sixty-two annual filings name each challenge as a risk, in substance.
| Rank | Challenge | Recognition |
|---|---|---|
| 1 | Supply Chain De-risking | 98% |
| 2 | Reimbursement & Coverage Compression | 78% |
| 3 | Severe VBP Margin Compression | 76% |
| 4 | Opaque Distributor Networks | 74% |
| 5 | Portfolio Separation & Regulatory Transfer | 60% |
| 6 | Regulatory Fragmentation | 58% |
| 7 | Product Quality, Recalls & Regulatory Enforcement | 56% |
| 8 | ESG & Sustainability Mandates | 56% |
| 9 | Strict Data Localization | 53% |
| 10 | Connected-Device Cybersecurity & Product Security | 53% |
| 11 | Post-Op Home Care Tracking | 43% |
| 12 | Value-Based Healthcare Pivot | 33% |
| 13 | Counterfeiting & Parallel Imports | 33% |
| 14 | Clinician Shortages & Training | 32% |
| 15 | Equipment Maintenance Downtime | 19% |
A low percentage is not evidence that a problem is small. Filings describe legal risk, not operations. Equipment servicing is a real cost for every capital-equipment manufacturer in this region, and 19% of filings name it. What the figure measures is disclosure.
Source: Amplifai analysis of 62 annual regulatory filings, read in full, August 2026. Method available on request.
Vetted solvers
How a solver earns a place on the roster
90 solvers on the roster. None of them got there by applying.
Proven against a named challenge
Evidence of solving at least one of the fifteen — not a claim to.
Advanced funding stage
Past seed, and capitalised well enough to deliver on an enterprise timeline.
Expertise from beyond MedTech
VR, logistics, SaaS, industrial AI, fintech-grade security. Cross-sector transfer is a selection criterion, not an exception.
Reference-checkable deployment
At least one live customer we can speak to — not a pilot deck.
APAC-ready
Able to operate in-region: entity, partner or distributor presence, and regulatory-pathway literacy.
Enterprise-grade posture
Data protection, security and quality practices that survive a MedTech vendor review.
Double opt-in only
No solver is introduced without confirming capacity and interest for that specific member.
Verification is manual. Roster admission is revocable.
How roster access works
The roster is not a directory and it is not browsable. Publishing 90 company names would turn a matching service into a list, and a list is worth less to everyone on it.
What happens instead: you confirm which of the fifteen challenges matter in which of your markets, we shortlist against that, and we approach the solvers we have shortlisted. No solver is introduced to you without confirming capacity and interest for your specific case, and no solver is told who asked until they have agreed to be introduced.
Members see the full roster with evidence grades inside the workspace. Timing for introductions is confirmed at intake.